KRAS and colorectal carcinoma: The CIF plots found that KRAS mutation had no association with the CSS of stage I (p = 0.347, Fig. 1B) and stage II (p = 0.093, Fig. 1C) CRC patients while it contributed to worse CSS in stage III (p = 0.009, Fig. 1D) and stage IV (p = 0.0013, Fig. 1E) CRC patients.